What cyber insurance do biotechs need for IPO readiness?

Pre-IPO biotechs face cyber exposure shaped by clinical trial data, sponsor-confidential data, and operational systems. Post-IPO, the same exposures persist but the consequences of a cyber incident expand materially: SEC disclosure obligations under Item 1.05 of Form 8-K (material cyber incident reporting within four business days), elevated securities-class-action exposure for delayed or incomplete disclosure, and shareholder derivative exposure tied to board oversight of cybersecurity.

Carriers underwriting cyber for public companies in the biotech category typically expect: documented information security program, SOC 2 Type II certification or equivalent, formal incident response plan, board-level cybersecurity oversight, and tested business continuity. The underwriting bar is materially higher than for private clinical-stage operators.

Pre-Series A / Series A clinical-stage biotech: $3M-$5M cyber sufficient for clinical trial data volume and sponsor-confidential data flow.

Series B/C clinical-stage with active trials and growing data volume: $5M-$10M cyber appropriate.

IPO readiness (S-1 filing in process or imminent): $10M-$25M cyber. Carriers often request 12-18 month lead time on the policy with progressive limit increases as the company matures.

Public clinical-stage: $15M-$50M+ depending on company size, data volume, and securities exposure. Standalone cyber typically supplemented by network security excess and dedicated tech E&O for any software products.

Notification expense and credit monitoring — standard but verify sub-limits relative to subject count.

Regulatory defense and fines — SEC, FTC, state AG, and HIPAA defense; sub-limits should not constrain at $250K when public-company regulatory exposure scales much higher.

Securities-related exposure — some cyber policies include limited coverage for cyber-incident-triggered securities claims; this overlaps with D&O and should be coordinated.

Ransomware coverage — full policy limit, no narrow sub-limits.

Business interruption — both first-party (operational systems) and contingent (third-party providers, e.g., CRO data systems, cloud providers).

Reputational harm and crisis management — increasingly important for public companies facing investor and customer scrutiny.

A public biotech cyber incident frequently produces two parallel litigation tracks: cyber regulatory and class-action work funded by cyber policy, and securities-class-action and derivative work funded by D&O. The two programs should be coordinated — defense counsel allocation, settlement strategy, and policy-limit erosion management benefit from advance coordination rather than ad-hoc allocation in the middle of a claim.

D&O underwriters for public biotechs increasingly request cyber policy documentation as part of D&O underwriting; the cyber posture is now treated as part of governance risk underwriting.